Efficacy of Pirtobrutinib Monotherapy in Treatment-Naïve Chronic Lymphocytic Leukemia: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Toby A Eyre, Lisa M Hess, Ehsan Masoudi...
https://pubmed.ncbi.nlm.nih.gov/41749915/Actively Recruiting
Led by Loxo Oncology, Inc. · Updated on 2026-08-17
737
Participants Needed
143
Research Sites
13 weeks
Total Duration
Researchers are studying the safety and effectiveness of pirtobrutinib LOXO-305 compared to ibrutinib in adults with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. The study includes participants who may or may not have received prior treatment for their cancer and focuses on those with specific genetic markers, like 17p deletions, in one part of the trial. This is a phase 3, open-label study sponsored by Loxo Oncology, Inc. Participants receive either pirtobrutinib or ibrutinib as oral treatments. The study has two parts Part 1 compares pirtobrutinib and ibrutinib in a broad group of participants and may last up to six years, while Part 2 evaluates pirtobrutinib alone in treatment-nafve participants with 17p deletions for up to two years. Treatments are taken by mouth, and participants are randomly assigned to treatment groups. During the study, participants will undergo regular assessments to monitor their response to treatment, including checking for complete or partial remission. Researchers will evaluate progression-free survival, overall survival, duration of response, and tolerability over several years. Safety and effectiveness are closely tracked with scheduled visits and tests until data cutoff or disease progression. Participation can last up to six years depending on the study part.
CONDITIONS
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Loxo Oncology, Inc.
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Pirtobrutinib | Ibrutinib | Current standard first‑line therapies |
|---|---|---|---|
| What it is | An investigational non‑covalent (reversible) BTK inhibitor tested orally in participants with CLL/SLL | An approved first‑generation BTK inhibitor taken orally, serving as the active comparator arm | Targeted therapies—such as BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) or fixed‑duration venetoclax combinations—are now standard first‑line options for CLL |
| Role in the trial | Investigational treatment arm | Active comparator designated as “ACTIVE_COMPARATOR” in the trial | Not part of trial but reflects treatments commonly used in first‑line CLL outside the study |
| Primary use | Treatment of CLL/SLL being evaluated as a possible first‑line option | Approved treatment for CLL/SLL used as standard therapy | Standard first‑line regimen options used in routine care for CLL/SLL |
| How it is given | Oral daily dosing, consistent with trial design | Oral daily dosing, as used in the trial active comparator arm | Oral administration for BTK inhibitors; venetoclax combinations include fixed‑duration oral or intravenous infusions per regimen |
| Regulatory status | Not yet approved for first‑line CLL/SLL; currently under investigation in this setting | Approved for first‑line CLL/SLL treatment | Approved agents or regimens that are guideline‑recommended for first‑line use |
| Evidence status | Efficacy and safety as first‑line therapy are being evaluated; no results published yet | Well‑established efficacy in first‑line CLL/SLL based on multiple trials and guideline support | Demonstrated efficacy in clinical trials for various regimens; widely endorsed in practice guidelines |
| Important risks | Not yet publicly available; safety profile will be assessed once trial results emerge | Known risks include atrial fibrillation, bleeding, hypertension, and infections based on clinical use | Safety profiles vary by regimen, including BTK inhibitors (cardiovascular and bleeding risks) and venetoclax regimens (risk of tumor lysis syndrome) |
| Important limitations | Efficacy and long‑term safety in first‑line CLL/SLL are not yet established | First‑generation BTK inhibitor with known off‑target effects and potential cardiovascular toxicities | Choice among multiple regimens may depend on patient comorbidities, duration (continuous vs fixed), and risk of side effects like tumor lysis or cardiovascular events |
| Patient impact | Unknown until trial results are available | Established benefit includes disease control and symptom improvement in many patients | Proven to extend progression‑free survival and improve quality of life in treated patients with CLL/SLL |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 6 years for Part 1; up to 2 years for Part 2
Participants receive either pirtobrutinib or ibrutinib orally as assigned in the study.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Toby A Eyre, Lisa M Hess, Ehsan Masoudi...
https://pubmed.ncbi.nlm.nih.gov/41749915/Jennifer A Woyach, Lugui Qiu, Sebastian Grosicki...
https://pubmed.ncbi.nlm.nih.gov/41353787/Loxo Oncology, Inc.
Lead Sponsor